Michael Ropacki - Oryzon Genomics Chief CNS

All Insiders . USA . 
Stock . Oryzon Genomics SA . Stakeholders . Insider . Michael Ropacki
ORYZF Stock  USD 3.36  0.00  0.00%   

Insider

Michael Ropacki is Chief CNS of Oryzon Genomics SA
Phone34 93 515 13 13
Webhttps://www.oryzon.com

Oryzon Genomics Management Efficiency

The company has return on total asset (ROA) of (0.0419) % which means that it has lost $0.0419 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0685) %, meaning that it generated substantial loss on money invested by shareholders. Oryzon Genomics' management efficiency ratios could be used to measure how well Oryzon Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
Oryzon Genomics SA has accumulated 10.35 M in total debt with debt to equity ratio (D/E) of 0.25, which may suggest the company is not taking enough advantage from borrowing. Oryzon Genomics SA has a current ratio of 3.68, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Oryzon Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Oryzon Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oryzon Genomics SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oryzon to invest in growth at high rates of return. When we think about Oryzon Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gaelle StadtlerTransgene SA
40
Sebastien MesnardOrpea SA
N/A
Anne LannerHansa Biopharma AB
54
Neville MDSanthera Pharmaceuticals Holdin
N/A
Eric FloydSilence Therapeutics plc
61
Klaus SindahlHansa Biopharma AB
N/A
Laurent LemaireOrpea SA
56
Xin FuJW Therapeutics Co
44
Yiping MDJW Therapeutics Co
59
MBA MBASilence Therapeutics plc
57
Stephen PinkertonOpen Orphan plc
N/A
Gem HopkinsSilence Therapeutics plc
N/A
Rhonda HellumsSilence Therapeutics plc
51
LLM JDTransgene SA
53
Laurent LannooGenfit SA
53
Leonard AddessoOrpea SA
N/A
FCMA CGMASanthera Pharmaceuticals Holdin
60
John StraffordSilence Therapeutics plc
N/A
Marie LindholmSilence Therapeutics plc
N/A
Lucie LarguierTransgene SA
N/A
Jrgen WittendorffSilence Therapeutics plc
N/A
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. The company was founded in 2000 and is based in Cornell de Llobregat, Spain. Oryzon Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 43 people. Oryzon Genomics SA [ORYZF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity-0.0685
Return On Asset-0.0419

Oryzon Genomics SA Leadership Team

Elected by the shareholders, the Oryzon Genomics' board of directors comprises two types of representatives: Oryzon Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oryzon. The board's role is to monitor Oryzon Genomics' management team and ensure that shareholders' interests are well served. Oryzon Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oryzon Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Saikat Nandi, Global Officer
Emili Cortada, Chief Officer
Enric Condomines, COO Operations
Xavier Ribera, Head Compliance
Michael Ropacki, Chief CNS
Jordi Pey, Chief Officer
Sonia Bezon, Chief Operations
Ana Limon, Sr Affairs
Carlos Arjol, Chairman, CoFounder
Neus Bernado, Chief Officer

Oryzon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oryzon Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.0685
Return On Asset-0.0419
Profit Margin(0.33) %
Operating Margin(0.72) %
Current Valuation106.94 M
Shares Outstanding55.26 M
Shares Owned By Insiders18.04 %
Shares Owned By Institutions0.72 %
Price To Book1.77 X
Price To Sales13.40 X

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce

Other Information on Investing in Oryzon Pink Sheet

Oryzon Genomics financial ratios help investors to determine whether Oryzon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY